🎁 Black Friday: up to 50% off of annual plans
Saluda Medical, Inc. (ASX:SLD)
Australia flag Australia · Delayed Price · Currency is AUD
0.1950
0.00 (0.00%)
Nov 20, 2026, 3:59 PM AEDT

Saluda Medical Earnings Call Transcripts

Fiscal Year 2027

Fiscal Year 2026

  • Evoke’s sensing and automated programming support durable outcomes with fewer than one reprogramming visit per year after the initial period. FY2027 Q1 growth, CAP24 paddle expansion and product redesigns underpin market and margin plans.

  • Revenue grew 28% year-over-year to $90.2M in FY 2026, with accelerating momentum and strong U.S. performance. FY 2027 guidance targets 25%–35% revenue growth and further gross margin expansion, driven by new product launches and sales force maturation.

  • Revenue grew 28% year-over-year to $90.2 million, exceeding guidance, with Q4 up 43%. FDA approval of the CAP24 paddle lead expands the addressable market by 30%. Cash position and operational efficiency improved, supporting continued growth into FY 2027.

  • Q3 saw 34% year-over-year revenue growth, driven by a 55% increase in U.S. patient implants and strong international performance. FY 2026 revenue guidance was raised to $87 million, with gross margin improvements expected from new product launches and operational efficiencies.

  • Saluda presented its closed-loop spinal cord stimulation technology, highlighting strong clinical outcomes, reduced therapy burden, and significant U.S. market expansion. Financial results show accelerating revenue, improved gross margins, and increased guidance for fiscal 2026.

  • Revenue grew 17% year-over-year to $39.4M in H1 FY26, with gross margin up to 49.4% and strong U.S. and international growth. FY26 revenue guidance reaffirmed at $85M, with improved cash burn and adjusted EBITDA expected.

Fiscal Year 2025

  • Investor update

    Raised AUD 231 million and began ASX trading to fund U.S. commercial expansion. Closed-loop spinal cord stimulation technology offers strong clinical outcomes, low therapy burden, and significant market opportunity, with a focus on rapid sales force growth and new reimbursement models.